All In Biotech

Drug Trial Radar · NCT03562169

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jun 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

406

Planned (sponsor's estimate)

Start

Mar 20, 2017

Primary completion

Mar 2026

Study completion Mar 2027

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Takeda
First posted
Jun 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: * The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor * The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS) Secondary objectives The secondary objectives of this study are to determine: * Overall survival * Time to disease progression * The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction * Time to next treatment * Progression-free survival 2 (PFS2) * Duration of response * Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion after ITD consolidation * Engraftment kinetics * Toxicity and safety * Quality of life (QoL) Participant population (refer to protocol section 9 for a full list of eligibility criteria). * Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT * First progressive disease (PD) at least 12 months since first ASCT, requiring therapy. * ECOG Performance Status 0-2 * Aged at least 18 years * Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function * Written informed consent Interventions: All participants will be registered at trial entry and will receive re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone (ITD), in order to reach maximum response. Participants who achieve at least stable disease (SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo a second randomisation to consolidation and maintenance or no further treatment. Participants randomised to consolidation and maintenance will receive treatment as follows: consolidation with 2 cycles of ITD and maintenance with ixazomib until disease progression. Number of participants: 406 participants will be registered into the trial to allow 284 participants to be randomised at the first randomisation (R1) and 248 participants to be randomised at the second randomisation (R2).

Conditions

  • Multiple Myeloma

Interventions

  • Ixazomib, thalidomide, & dexamethasone (ITD) re-inductionDrug

    4 - 6 ITD 28-day cycles as follows: * Ixazomib 4mg capsule on days 1, 8 and 15 * Thalidomide 100mg capsule on days 1-28 * Dexamethasone 40mg tablets on days 1, 8, 15 and 22

  • Conventional autologous stem cell transplant (ASCT-con)Drug

    Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.

  • Augmented autologous stem cell transplant (ASCT-aug)Drug

    Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.

  • ITD consolidation and ixazomib maintenance vs. No further therapyDrug

    Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression. Participants randomised to ITD consolidation and ixazomib maintenance will receive: Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: 100 days post-ASCT
  2. Progression-free survivalTime frame: From date of registration to date of disease progression, up to 120 months.

Locations

91 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • Monklands Hospital

    Airdrie, United Kingdom · Recruiting

  • University Hospital Ayr

    Ayr, United Kingdom · Recruiting

  • Barnsley Hospital

    Barnsley, United Kingdom · Recruiting

  • Basingstoke & North Hampshire Hospital

    Basingstoke, United Kingdom · Recruiting

  • Royal United Hospital

    Bath, United Kingdom · Recruiting

  • Good Hope Hospital

    Birmingham, United Kingdom · Recruiting

  • Heartlands Hospital

    Birmingham, United Kingdom · Recruiting

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom · Recruiting

  • Blackpool Victoria Hospital

    Blackpool, United Kingdom · Recruiting

  • Pilgrim Hospital

    Boston, United Kingdom · Recruiting

  • Royal Bournemouth Hospital

    Bournemouth, United Kingdom · Recruiting

  • Bradford Royal Infirmary

    Bradford, United Kingdom · Recruiting

  • Bristol Haematology & Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Southmead Hospital

    Bristol, United Kingdom · Recruiting

  • Queen's Hospital

    Burton-on-Trent, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • St Helier Hospital

    Carshalton, United Kingdom · Recruiting

  • Cheltenham General Hospial

    Cheltenham, United Kingdom · Recruiting

  • Countess of Chester Hospital

    Chester, United Kingdom · Recruiting

  • Chesterfield Royal Hospital

    Chesterfield, United Kingdom · Recruiting

  • St Richards Hospital

    Chichester, United Kingdom · Recruiting

  • University Hospital Coventry

    Coventry, United Kingdom · Recruiting

  • Royal Derby Hospital

    Derby, United Kingdom · Recruiting

  • Dewsbury Hospital

    Dewsbury, United Kingdom · Recruiting

  • Russells Hall Hospital

    Dudley, United Kingdom · Recruiting

  • Ninewells Hospital

    Dundee, United Kingdom · Recruiting

  • Hairmyres Hospital

    East Kilbride, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • Beatson Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • New Victoria Hospital

    Glasgow, United Kingdom · Recruiting

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom · Recruiting

  • Grantham and District Hospital

    Grantham, United Kingdom · Recruiting

  • Diana Princess of Wales Hospital

    Grimsby, United Kingdom · Recruiting

  • Calderdale Royal Hospital

    Halifax, United Kingdom · Recruiting

  • Harrogate District Hospital

    Harrogate, United Kingdom · Recruiting

  • Huddersfield Royal Infirmary

    Huddersfield, United Kingdom · Recruiting

  • Castle Hill Hospital

    Hull, United Kingdom · Recruiting

  • Raigmore Hospital

    Inverness, United Kingdom · Recruiting

  • Ipswich Hospital

    Ipswich, United Kingdom · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.